Skip to main content
Premium Trial:

Request an Annual Quote

Applied Markets Watch: Promega GenePrint 10 System

Premium

Promega has launched the GenePrint 10 system for human cell line authentication and sample identification.

Tissue culture cells are often misidentified or contaminated with other cells, wasting substantial time, effort, and laboratory resources and potentially invalidating published data, Promega said. The National Institutes of Health and many journals now recommend or require cell line authentication before grant approval or acceptance for publication.

GenePrint 10 includes the eight loci recommended by the ANSI Standard Authentication of Human Cell Lines: Standardization of STR Profiling; plus amelogenin for gender identification and the highly polymorphic D21S11 locus for additional power of discrimination. Short tandem repeat analysis begins with amplification, and the GenePrint 10 system contains all materials necessary to co-amplify human STR loci using a hot-start thermostable DNA polymerase and a robust buffer compatible with fast cycling and direct amplification from substrates.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.